. Biologically, genetic polymorphism can be thought of as an organizational arrangement whereby variability is structured into the population to give it a better chance of survival should changes occur in the environment (4) . Genetic polymorphism has been linked to three classes of phenotypes based on the extent of drug metabolism.
Extensive metabolism (EM) of a drug is characteristic of the normal population; poor metabolism (PM) is associated with cumulation of specific drug substrates and is typically an autosomal recessive trait requiring mutation and (or) deletion of both alleles for phenotypic expression;
and ultra-extensive metabolism (UEM) results in increased drug metabolism and is an autosomal dominant trait arising from gene amplification. The latter class of phenotypes is rare and has only been described for certain polymorphisms.
Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug (1, 5) . It has been shown that significant ethnic differences exist in the frequency of the PM phenotype (6). There are, for example, significant interethnic differences in the prevalence of polymorphism of the 2D6 subfamily of cytochrome P450 enzymes (CYP450; P450). In Northern American and European Caucasian populations, the prevalence of the PM phenotype is 5-10% (I). However, the prevalence in American blacks is 1.8%, in native Thai 1.2%, 1.0% in Chinese, 2.1% in native Malay population, and apparently absent in the Japanese population (I). Polymorphism in metabolism will generally only have serious consequences if the drug has a narrow therapeutic window: at low concentrations, the efficacy of the drug is minimal, whereas at high concentrations, the drug may be toxic. Therefore, a narrow therapeutic window requires a clinical detection method for the existence of a possible polymorphism in metabolism of a particular drug (7, 8 ).
An identical dosage could result in widely different concentrations of the therapeutically active compound (9). Besides variation due to polymorphism, other factors in the pharmacokinetic phase (such as absorption, distribution and clearance) and the pharmaco-dynamic phase (such as host sensitivity) are responsible for the interpatient variation. The possibility that some anticancer drugs are metabolized by enzymes exhibiting a genetic polymorphysm (e.g. certain CYP450 enzymes) should be considered (10-13). This could be of clinical relevance with anticancer drugs because these drugs are normally administered at a dose that results in maximal tolerable toxicity. Poor metabolizers would face an increased risk of adverse effects, while extensive metabolizers might exhibit subtherapeutic plasma concentrations (provided that no important active metabolites are formed) (9). The role of polymorphism in the metabolism of the family of antidepressant drugs, for example, has been, and still is, heavily investigated (14-17). CYP2D6 catalyses the metabolism of various antidepressant drugs, and knowledge of the drug metabolism status of a patient has shown to be helpful in the selection of patients for CYP2D6 activity should be routine practice prior to the commencement of treatment with antidepressant agents. However, the relevance of this practice has been the subject of much debate, and other approaches such as limited sampling pharmacokinetic studies, which allow a direct assessment of interpatient variability, provides a feasible alternative (14). Currently, mutant alleles and other alleles are being cloned and sequenced, which has resulted in the development of allele-specific polymerase chain reaction (PCR) assays that can be used for the routine screening of patients for CYP2D6 activity and therefore for their ability to metabolize antidepressant agents (I 4).
The goal of this review is to examine the role of specific P450 enzymes in the metabolism of a group of frequently used anticancer drugs in humans (Table I) , and to discuss the possibility of utilizing pharmacogenetic information as a tool to individualize chemotherapy.
This could contribute to the prevention of altered effectiveness and severe toxicity experienced by some patients treated with these drugs.
Materials and methods
The literature used for this review was obtained after a thorough search using Medline (1966-03/1997), Current Contents (06/10/1996-06/09/1997) and the search-option at the Internet site of the National Library of Medicine (PubMed; http://www.ncbi.nlm.nih.gov/PubMed), combined with articles arising from the literature found by this search. The keywords used for this search were: cytochrome P450, biotransformation and elimination, individually combined with the selected anticancer drugs (Table I) . This search produced a total number of 255 articles from which a selection was made for this review of the interesting and useful material. Estimates of the total number of functional P450 genes in mammalian species range between at least 60 to more than 200 (27). All of these genes are believed to have arisen by divergent evolution, i.e. from a common ancestral probably more than 2.5 billion years ago. A major driving force for the large number of gene duplications is believed to be animal-plant 'warfare' (19, 28-30). Between two species, there are already numerous examples of different P450 genes, and, in some cases, different catalytic activity among members of the same P450 gene subfamily (19,301. It is possible that a particular test compound will produce an entirely different response, with regard to toxicity or carcinogenicity, between a human and a laboratory animal, due to the presence or absence of a particular P450 gene in either species (7).
Enzymes involved in drug metabolism
P450 enzymes of the CYP2C, CYP2D and CYP3A subfamilies are the most active in metabolizing known clinically used drugs ( 
Phenotyping vs genotyping
The possibility of distinguishing the three classes of metabolizers (PM, EM or UEM) prospectively would allow appropriate modifications in patient treatment.
The specific drug metabolism may be identified by either phenotyping or genotyping.
Phenotyping is a procedure whereby at first a test drug is administered of which metabolism is known to be solely dependent on the function of a specific drug metabolizing enzyme, followed by measurement of the metabolic ratio (MR). The MR is the ratio of drug dosage or unchanged drug to metabolic measured in serum or urine. Each specific CYP450 enzyme corresponds with its own specific test drug which can be used to define the activity of the CYP450 enzyme. Gonzalez et al. (31) Genotyping offers the possibility to identify specific genetic mutations which cause certain drug metabolic phenotypes.
There are two approaches currently used for the detection of specific mutations within genes associated with altered drug metabolism.
With the first method, the specific region of a certain gene is amplified by using the technique of polymerase chain reaction (PCR) followed by digestion of the produced DNA with specific restriction endonucleases (I). The differences in size of the DNA fragments obtained as a result of endonuclease digestion are referred to as restriction fragment length polymorphism (RFLP) (81, and the exact size of the digestion products are determined by agarose gel electrophoresis. The second approach for the detection of possible mutations within a gene is by means of allele-specific PCR amplification (I). In this procedure, oligonucleotides specific for hybridizing with the common or variant alleles are utilized in parallel amplification reactions. These two possible methods for genotyping have a few interesting advantages compared to phenotyping:
there is no disturbance from underlying disease or drugs taken by the investigated individual, rapid intervention is possible since results are provided within 48-72 h and only small amounts of blood or tissue are necessary for these genotyping methods (1, 37). The fact that genotyping is probably less of a burden for the individual patient (e.g. only small amounts of blood are required) and that the required information obtained is more rapidly available compared to phenotyping, makes this technique very interesting since the question of practicality of phenotyping vs genotyping will probably play a major role in the clinical setting. has been shown to be effective against a wide spectrum of solid tumours both as a single agent or as a part of combined therapy, and is used in the treatment of both paediatric and adult malignancies (42, 43). The structure and metabolism of cyclophosphamide and ifosfamide show much resemblance, but ifosfamide produces less myelosuppression than cyclophosphamide and also exhibits little cross-resistance (44). There are two pathways of metabolism of these drugs which are important and should be discussed: firstly the activation step and secondly an important route of detoxification.
The activation of both cyclophosphamide and ifosfamide is initiated with the ring oxidation at C4 (4-hydroxylation) (39 (72) . Importantly, in 27% of the preparations used in this study, the metabolites named 'B' and 'C' were the predominant metabolites rather than Ga-hydroxytaxol.
In both the studies by Rahman et al. (69) and Sonnichsen et a/. (72) it has been shown that the formation of Ga-hydroxytaxol is catalysed by human CYP2C8, and that it is the result of region-specific hydroxylation at position six of the taxane ring, with the 6-hydroxyl group tram to the 7-hydroxyl group.
However, a few studies showed that several CYPSA substrates inhibited formation of Ga-hydroxytaxol (60, 67, 71, 72). Metabolite B is more polar than Ga-hydroxytaxol and has been identified in human bile, after human liver incubations and in rodents (60, 65, 68, 70). This metabolite is formed by a single hydroxylation at the para-position of the C3 phenyl group on the Cl3 side chain of paclitaxel, and is catalysed by CYP3A4 (60, 67, 70), which was concluded from chemical inhibition, metabolic correlation and immuno-inhibition studies as well as using heterologously expressed P450.
Metabolite A is also a more polar substance than Ga-hydroxytaxol and it has been shown that this dihyroxylated metabolite is formed by stepwise hydroxylations by CYP2C8 and -3A4 at the two sites previously described for Ga-hydroxytaxol and metabolite B (60). Sonnichsen et al. (72) described a paclitaxel metabolite, named 'C' with elution characteristics which had not been described previously. Based on the results of high correlations with the formation of metabolite B and the midazolam 4-hydroxylation which are both substrates of CYP3A4 they stated this metabolite was formed by CYP3A4.
In summary, it can be concluded that 6a-hydroxytaxol, metabolites B, C and A are formed by CYP2C8, -3A4, -3A4 and both -2C8 and -3A4, respectively, but that Ga-hydroxytaxol is not the predominant paclitaxel metabolite in all individuals.
The CYP3A4 isozyme may play a role in the metabolism and substantial interpatient variability in the clearance of paclitaxel. A poor metabolizer (PM) for CYP2C8 or CYP3A4 will probably experience increased toxicity if paclitaxel is administered, since these two enzymes play a major role in the elimination of this antineoplastic drug.
Tamoxifen
Tamoxifen was developed in the late 1960s as an anti-oestrogen. The drug inhibits oestrogen-stimulated cell division, but in some tissues it can also exhibit oestrogen-like activities (76) . Tamoxifen is of proven efficacy in inhibiting the growth of oestrogen-receptor-positive breast cancers (76) (77) (78) (79) . Tamoxifen has also a number of beneficial effects apart from its primary action on breast cancer cells. In treated women, it has caused a significant reduction in serum cholesterol, and possibly in the incidence of fatal myocardial infarction (76). However, tamoxifen has only limited efficacy, with only one-third of patients gaining benefit from the drug (80). It has been suggested that tamoxifen can also be used as a preventing agent for breast cancer for women at risk for developing this disease (81). However, in this regard, there is some concern being expressed over the potential of tamoxifen to cause hepatic and endometrial cancers (82-84). The metabolism of tamoxifen shows a large interindividual variation, which might be a determinant of the efficacy and toxicity of this drug (85). The primary route of metabolism is N-demethylation, and the minor routes include Noxidation, and 4-and 4'-hydroxylation.
It has been shown in a few studies that CYP3A plays a role in catalysing the N-demethylation of tamoxifen (85-89). Jacololet et al. (86) were the first to show that the CYP3A family plays a significant role in the tamoxifen N-demethylation but they were unable to distinguish between closely related CYP3A forms involved in this metabolism of tamoxifen.
The They found CYP3Al to be the major catalyst of this reaction although they were unable to reconstitute the N-demethylation activity with purified CYP3Al (88). The study by Mani et a/. (88) also showed that CYP2Bl was not involved in the N-demethylation reaction, and that CYPIAI also does not contribute significantly.
Both Crewe et a/. (85) and Simon et a/. (89) reported that this reaction is catalysed predominantly by CYP3A4 with a possible contribution from CYPIA (89). It is likely that a poor metabolizer (PM) for any one of the CYP450 enzymes which play a role in the N-demethylation of tamoxifen (e.g. CYPIA, -2C, 3A1, 3A4) will experience increased toxicity when tamoxifen is administered, since in that case tamoxifen will be eliminated at a lower rate than expected by this route of metabolism.
Although plasma and tumour concentrations of 4-hydroxytamoxifen are only about 2% of those of the parent compound, 4-hydroxylation also is an important pathway of tamoxifen metabolism because the product of this reaction is intrinsically 100 times more potent as an oestrogen antagonist than the parent drug and thus may contribute to the clinical efficacy (85). Some authors have indicated that CYP2C might play a role in this reaction (87, 90). However, these results were obtained using inhibitory antibodies raised against rat CYP2C, which have questionable specificity compared to the human forms of CYP2C. Recently, the first step has been made in the identification of the CYP isoform specificity of tamoxifen 4-hydroxylation in humans by Crewe et al. (85). The findings of the investigators showed, by using the microsomes of 10 human livers, the involvement of CYP2D6, -2C9 and -3A4 in the 4-hydroxylation of tamoxifen (85). Furthermore, they found that the whole 4-hydroxylation activity could be accounted for by the sum of these activities and they had strong indications that metabolism by CYP2D6 was the most important determinant of the rate of 4-hydroxylation of tamoxifen in human livers (85). However, the authors of this study suggest that the marked interindividual variation in the contribution of these isoforms underlines the need for study of metabolic reactions in a sufficient number of livers that are characterized with respect to a range of cytochrome P450 activities.
Thio-TEPA Thio-TEPA (N,N'N"-triethylenethiophosphoramide) is an alkylating anticancer drug which is currently used for chemotherapy of a number of malignancies, including metastatic carcinoma of the breast, ovarian, bladder and meningeal carcinoma (91-93). The precise mechanism of action of thio-TEPA remains unknown, but DNA is believed to be the primary target of this cytotoxic agent (94).
A major route of thio-TEPA metabolism in both rodents and humans is the oxidative desulphuration to the pharmacologically active TEPA (N,N'N"-triethylenephosphoramide) (94-99). In this reaction which was shown to be catalysed by cytochrome P450 (100, 101). In this reaction there is also the formation of a diffusible, chemically reactive species which has been shown to be elemental sulphur (951, and this substance can inactivate liver CYP and other enzymes (97, 98) and thus dramatically enhance the cytotoxicity of thio-TEPA in culture (94). It has been reported that this oxidative desulphuration of thio-TEPA to TEPA is carried out by CYP2B1, -2C6 and -2Cll in rat liver (94, 95) .
Although TEPA has pharmacologic activity in vitro, the contribution of this metabolite to the overall in vivo cytotoxicity is still unclear (95). For example, the activity of TEPA as a cytotoxic agent in cell culture is not more active than thio-TEPA (94). Chang et al. (95) found that induction of hepatic thio-TEPA oxidation reduces tumour growth delay effects, whereas inhibition of the liver CYP-catalysed thio-TEPA metabolism both enhances antitumour activity and exacerbates systemic toxicity. They postulated that the therapeutically significant cytotoxic metabolites in viva are distinct from TEPA or any other metabolite derived from the oxidative desulphuration pathway (95). Ng et a/. (94) also reported that TEPA is not the source of cytotoxic activity but rather results from the associated production of reactive metabolites which are distinct from TEPA. They also stated the possibility that the cytotoxic effect of the thio-TEPA-derived reactive metabolites may result from their action at the cell surface (94).
Egorin et a/. (102) reported that in addition to the CYP-dependent oxidative desulphuration pathway, thio-TEPA can also be converted to N,N'-diethylenethiophosphoramide and aziridine by a route that is probably CYPindependent.
Chang et al. (95) suggested that one or both of these metabolites may be important mediators of the thio-TEPA cytotoxicity in viva, and that the formation of these reactive species occurs either non-enzymatically or is catalysed by enzymes distinct from CYP2Bl and CYP2Cll.
Vinblastine and vincristine
Vinblastine and vincristine are two naturally occurring Inca alkaloids extracted from the Catharanthus plant species (103). They belong to the Inca alkaloid family together with vindesine and navelbine. Vinblastine and vincristine are currently applied as very effective anticancer drugs both as single agent and in combination with other drugs (103, 104). Vinblastine is frequently applied in the treatment of Hodgkin's and non-Hodgkin's lymphoma as well as some solid tumours such as testicular and breast cancer (103, 1041, whereas vincristine is particularly effective against acute lymphatic leukaemia, Wilms' tumour, rhabdomyosarcoma and various lymphomas (103). Although these substances are structurally related, there have been observed marked differences in their antitumour activity as well as in their toxicity and pharmacokinetic behaviour (105, 106). The clinical pharmacokinetics of the Inca alkaloids present large inter-and intra-individual variation (103). The suggestion has been made that the interpatient pharmacokinetic variability may be dependent upon individual differences in hepatic drug disposition (106). To date, there has been only one study investigating the role of cytochrome P450 enzymes in the metabolism of vinblastine (104). In this study, Zhou-Pan et al. showed that vinblastine was metabolized to one main metabolite by human liver microsomes.
However, after incubation of vinblastine with freshly isolated hepatocytes in suspension, the drug showed a biotransformation pattern characterized by at least four metabolites.
Therefore it is concluded that both cytosolic and microsomal enzymes must be involved in the metabolism of vinblastine (104). The authors showed a wide interindividual variation in the metabolism of vinblastine and they found it to be mediated by the CYP3A subfamily (104).
There have not been any reports of P450 mediated or catalysed vincristine metabolism.
However,Zhou eta/. (107) demonstrated the involvement of CYP3A isozymes in the metabolism of vindesine of vindesine by using a bank of human liver microsomes and they also reported large interindividual variations in the metabolism of vindesine. Since CYP3A4 plays a role in the elimination of vinblastine and vindesine, it HAL. is likely that administration of either one of these antineoplastic drugs to a poor metabolizer (PM) of CYP3A4 will lead to increased host toxicity.
Miscellaneous 5-Fluorouracil was reported to suppress some P450-mediated drug metabolizing reactions in the rat (1081, whereas methotrexate was found to induce a decrease in cytochrome P450 level and activities in rats (109). Furthermore, it has been shown thatthe activation of the prodrug 6-mercaptopurine occurs intracellularly, whereas the contribution of the three major metabolic pathways involved (thiopurine methyltransferase, xanthine oxidase and hypoxanthine phosphoribosyltransferase)
in the individual variations in the metabolism of 6-mercaptopurine are still the subject of pharmacogenetic studies (110). It has been shown that after a standard dosage of 6-mercaptopurine, there is a large interindividual variation in the formation of the 6-thioguanine nucleotide metabolites, due to the thiopurine methyltransferase genetic polymorphism (110). In children with high inherited activities of thiopurine methyltransferase, low concentrations of 6-thioguanine nucleotides are formed after a standard dose of 6-mercaptopurine, resulting in a high risk of disease relapse (110, Ill). In the case of the remaining selected anticancer drugs, there is no information about the possible involvement of P450 in their metabolism or elimination. The different P450 isozymes which play a role in the activation or elimination of the investigated anticancer drugs, including the expected effects of polymorphism, are summarized in Table 3 . 
